Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative

Research output: Contribution to journalPublished meeting abstract


Background: As part of I-O Optimise, a multinational research platform providing real-world insights into the management of lung cancers, the SCAN-LEAF study aims to describe the epidemiology, clinical care and outcomes for pts with NSCLC in Scandinavia. We report initial Tx and OS for pts with NSCLC prior to the availability of immunotherapies in Sweden. Methods: The analysis includes all adult pts diagnosed with NSCLC at Uppsala and Karolinska (Stockholm) University Hospitals from 2012 to 2015 (follow-up to Dec 2016). Electronic medical record data were extracted using Pygargus CXP software and linked with national registries. Bespoke rule-based algorithms were applied to describe Tx patterns; Kaplan–Meier methods were used to estimate OS. Results: 2779 pts were diagnosed with incident NSCLC (median age, 70 yrs [range: 22–96; 14.2% ≥80]; male, 48.5%; histology: non-squamous (NSQ), 70.9%, squamous (SQ), 17.7%, other, 11.4%; stage distribution: I, 19.3%; II, 7.7%; IIIA, 12.3%; IIIB, 7.2%; IV, 51.2%). Initial Tx (≤6 months from diagnosis) by stage and yr of diagnosis is shown in the table. Median OS (months) for NSQ and SQ pts: not reached and 52.8 in stage I, 43.2 and 23.6 in stage II, 26.7 and 20.4 in stage IIIA, 12.5 and 12.9 in stage IIIB, and 7.6 and 6.1 in stage IV, respectively. Among stage IIIB–IV pts, 60.7% (NSQ) and 53.5% (SQ) had ≥1 line of systemic anti-cancer therapy (SACT); median OS was 12.2 (NSQ) and 10.4 (SQ) months in pts on SACT, and 3.1 (NSQ) and 3.7 (SQ) months in pts not on SACT. Ongoing analyses will assess factors associated with SACT receipt in stage IIIB–IV pts. Conclusions: Swedish pts with NSCLC had a high burden of disease, with most diagnosed at stage IV and a median OS of 1 yr in late-stage pts receiving SACT. There is also scope for improved prognosis in pts diagnosed at early stages, particularly in SQ pts. Future analyses will assess the potential impact of recent improvements in diagnostics and therapeutics on Tx patterns and OS in Swedish NSCLC pts.


  • S. Ekman
  • J. B. Sørensen
  • O. T. Brustugun
  • P. Horvat
  • D. Patel
  • M. Rosenlund
  • A. Mette Kejs
  • A. Juarez-Garcia
  • M. Daumont
  • L. Lacoin
  • J. R. Penrod
  • J. C. O'Donnell
  • M. Planck
External organisations
  • Karolinska Institutet
  • Copenhagen University Hospital
  • Skåne University Hospital
  • Vestre Viken Hospital Trust
  • IQVIA, United Kingdom
  • IQVIA Nordics, Sweden
  • IQVIA Nordics, Denmark
  • Bristol-Myers Squibb in Uxbridge
  • Bristol-Myers Squibb, Belgium
  • Bristol-Myers Squibb
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)ii17
Number of pages1
JournalAnnals of Oncology
Issue numberSuppl 2
Publication statusPublished - 2019 Apr
Publication categoryResearch

Related research output

Sørensen, J. B., Ekman, S., Brustugun, O. T., Horvat, P., Patel, D., Rosenlund, M., Mette Kejs, A., Juarez-Garcia, A., Daumont, M., Lacoin, L., Penrod, J. R., O'Donnell, J. C. & M. Planck, 2019 Apr, In : Annals of Oncology. 30, Suppl 2, p. ii16-ii17

Research output: Contribution to journalPublished meeting abstract

View all (1)